Breaking News Instant updates and real-time market news.

SBBP

Strongbridge Biopharma

$5.89

0.49 (9.07%)

07:42
03/25/19
03/25
07:42
03/25/19
07:42

Strongbridge Biopharma presents new data from SONICS study at IPC, ENDO

Strongbridge Biopharma announced the presentation of new data analyses from the Phase 3 SONICS study of Recorlev for the potential treatment of endogenous Cushing's syndrome. Secondary endpoint results were presented at the International Pituitary Congress, or IPC and a subgroup analysis was presented at the Endocrine Society, or ENDO. Mean urinary-free cortisol, or mUFC, normalization with Recorlev was similar in patients with and without diabetes. Improvements in hemoglobin A1c and fasting blood glucose in the maintenance phase were more pronounced among patients with comorbid diabetes mellitus, while anti-diabetic medications were more often decreased than increased. Significant improvements in cardiovascular risk markers of low-density lipoprotein cholesterol, weight, body mass index and waist circumference were seen in patients with and without diabetes mellitus. Additionally, improvement in LDL-cholesterol occurred without any new use of statins or increases in statin dose. The most common treatment-emergent adverse events in patients with diabetes mellitus were nausea, vomiting and urinary tract infection, headache, peripheral edema and hypertension were most common among patients without diabetes mellitus. Recorlev treatment led to sustained reductions in both mUFC and late night salivary cortisol levels over a six-month maintenance treatment period. Adrenocorticotrophic hormone levels in the subset of patients with Cushing's disease increased about two-fold from baseline to the end of the maintenance phase. Recorlev was generally well-tolerated with no unexpected safety signals observed during the study.

SBBP Strongbridge Biopharma
$5.89

0.49 (9.07%)

06/28/18
JANY
06/28/18
INITIATION
Target $13
JANY
Buy
Strongbridge Biopharma initiated with a Buy at Janney
Janney initiated Strongbridge Biopharma with a Buy and $13 price target.
08/08/18
JANY
08/08/18
NO CHANGE
Target $16
JANY
Buy
Strongbridge price target raised to $16 from $13 at Janney Montgomery Scott
Janney Montgomery Scott analyst Esther Hong raised her fair value estimate on Strongbridge Biopharma to $16 after the company announced its Phase 3 SONICS study of recorlev in Cushing's syndrome achieved the primary endpoint of normalized UFC during a 6-month period without a dose increase. Hong, who believes recorlev's demonstration of a clinically meaningful impact on comorbidities and a more favorable liver-tolerability profile compared to ketoconazole will drive uptake, keeps a Buy rating on Strongbridge shares.
11/01/18
STFL
11/01/18
NO CHANGE
Target $15
STFL
Buy
Stifel says Strongbridge makes 'right move' to improve Recorlev clinical package
Stifel analyst Annabel Samimy acknowledged that Recorlev development timelines are pushed out by Strongbridge Biopharma (SBBP) expanding LOGICS to strengthen the clinical package. While this results in a three-quarter delay, with top-line now expected in the fourth quarter of 2019 and the launch expectation pushed out to 2021, he believes the company is ultimately making "the right move." He added that the sale of North American rights of Macrelin to Novo Nordisk (NVO) represents a 7.5x return in less than 2 years, but that was overshadowed by Q3 results that showed Keveyis adoption is "proving more challenging." Samimy keeps a Buy rating and $15 price target on Strongbridge Biopharma shares.
12/18/18
LDLW
12/18/18
INITIATION
Target $11
LDLW
Buy
Strongbridge Biopharma initiated with a Buy at Laidlaw
Laidlaw analyst Francois Brisebois started Strongbridge Biopharma with a Buy rating and $11 price target, stating that he views the stock as undervalued at current levels given what he sees as "strong" PHASE 3 Recorlev data and the "impressive commercial potential" of Macrilen.

TODAY'S FREE FLY STORIES

EADSY

Airbus

$0.00

(0.00%)

, BA

Boeing

$346.47

-3.535 (-1.01%)

06:11
12/13/19
12/13
06:11
12/13/19
06:11
Periodicals
Qantas picks Airbus over Boeing for world's longest flights, Reuters reports »

Qantas Airways has…

EADSY

Airbus

$0.00

(0.00%)

BA

Boeing

$346.47

-3.535 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEX

NexTier Oilfield

$6.28

0.36 (6.09%)

, FTI

TechnipFMC

$19.90

0.55 (2.84%)

06:10
12/13/19
12/13
06:10
12/13/19
06:10
Recommendations
NexTier Oilfield, TechnipFMC, Helmerich & Payne, Nine Energy Services analyst commentary  »

NexTier Oilfield,…

NEX

NexTier Oilfield

$6.28

0.36 (6.09%)

FTI

TechnipFMC

$19.90

0.55 (2.84%)

HP

Helmerich & Payne

$42.62

1 (2.40%)

NINE

Nine Energy Services

$6.20

0.44 (7.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

EADSY

Airbus

$0.00

(0.00%)

06:08
12/13/19
12/13
06:08
12/13/19
06:08
Hot Stocks
Airbus acquires industrial automation company MTM Robotics »

Airbus has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$62.58

0.87 (1.41%)

06:06
12/13/19
12/13
06:06
12/13/19
06:06
Initiation
ConocoPhillips initiated  »

ConocoPhillips initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

  • 23

    Mar

OGI

Organigram

$2.57

(0.00%)

06:06
12/13/19
12/13
06:06
12/13/19
06:06
Hot Stocks
Organigram gets Health Canada's approval for 16 additional cultivation rooms »

Organigram is pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

OIS

Oil States

$17.64

0.55 (3.22%)

06:06
12/13/19
12/13
06:06
12/13/19
06:06
Downgrade
Oil States rating change  »

Oil States downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

SSNLF

Samsung

$0.00

(0.00%)

06:06
12/13/19
12/13
06:06
12/13/19
06:06
Periodicals
Samsung VP receives jail term for union-busting activities, Reuters reports »

Samsung Electronics VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBI

Hanesbrands

$15.18

0.19 (1.27%)

06:04
12/13/19
12/13
06:04
12/13/19
06:04
Downgrade
Hanesbrands rating change  »

Hanesbrands downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGS

Regis

$17.31

0.15 (0.87%)

06:03
12/13/19
12/13
06:03
12/13/19
06:03
Hot Stocks
Regis enters franchise arrangement with Bushell Investment Group »

Regis announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTEN

Patterson-UTI

$10.38

0.29 (2.87%)

06:03
12/13/19
12/13
06:03
12/13/19
06:03
Downgrade
Patterson-UTI rating change  »

Patterson-UTI downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

PTEN

Patterson-UTI

$10.38

0.29 (2.87%)

06:03
12/13/19
12/13
06:03
12/13/19
06:03
Downgrade
Patterson-UTI rating change  »

Patterson-UTI downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

MOH

Molina Healthcare

$129.62

1.725 (1.35%)

06:00
12/13/19
12/13
06:00
12/13/19
06:00
Hot Stocks
Molina Healthcare announces $500M share repurchase program »

Molina Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBAN

Huntington Bancshares

$15.59

0.39 (2.57%)

05:58
12/13/19
12/13
05:58
12/13/19
05:58
Downgrade
Huntington Bancshares rating change  »

Huntington Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$271.45

0.74 (0.27%)

05:58
12/13/19
12/13
05:58
12/13/19
05:58
Periodicals
Apple acquires U.K.-based Spectral Edge, Bloomberg reports »

Apple has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUGRY

United Utilities

$0.00

(0.00%)

05:55
12/13/19
12/13
05:55
12/13/19
05:55
Upgrade
United Utilities rating change  »

United Utilities upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HINOY

Hino Motors

$0.00

(0.00%)

05:54
12/13/19
12/13
05:54
12/13/19
05:54
Downgrade
Hino Motors rating change  »

Hino Motors downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAO

Youdao

$14.18

-0.17 (-1.18%)

05:54
12/13/19
12/13
05:54
12/13/19
05:54
Initiation
Youdao initiated  »

Youdao initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASAZY

Assa Abloy

$0.00

(0.00%)

05:53
12/13/19
12/13
05:53
12/13/19
05:53
Upgrade
Assa Abloy rating change  »

Assa Abloy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATDRY

Auto Trader Group

$0.00

(0.00%)

05:53
12/13/19
12/13
05:53
12/13/19
05:53
Upgrade
Auto Trader Group rating change  »

Auto Trader Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDNNY

Boliden

$0.00

(0.00%)

05:51
12/13/19
12/13
05:51
12/13/19
05:51
Downgrade
Boliden rating change  »

Boliden downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$220.43

0.37 (0.17%)

, REGN

Regeneron

$372.10

-1.41 (-0.38%)

05:39
12/13/19
12/13
05:39
12/13/19
05:39
Recommendations
Vertex, Regeneron analyst commentary  »

Credit Suisse replaces…

VRTX

Vertex

$220.43

0.37 (0.17%)

REGN

Regeneron

$372.10

-1.41 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

OPI

Office Properties

$32.93

-1.02 (-3.00%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Downgrade
Office Properties rating change  »

Office Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOLVY

Volvo

$0.00

(0.00%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Hot Stocks
Volvo appoints Scott Rafkin as Chief Digital Officer »

Scott Rafkin, currently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$236.18

2.22 (0.95%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Recommendations
Amgen analyst commentary  »

Amgen price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$162.94

-4.5 (-2.69%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Upgrade
Nordson rating change  »

Nordson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.